Please assess the completion status of the following clinical trial:

Trial Title: Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. All participants must be 18 years or older.~2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.~3. Individuals with medically stable Parkinson's disease (in the opinion of the investigator).~4. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.~5. Absence of dementia in all subjects, as determined by pre-scanning cognitive assessment.~6. Control subjects who are able to undergo MRS~Exclusion Criteria:~1. Inability to undergo MRI scanning without sedation~2. Medically unstable conditions in any group as determined by the investigators~3. Pregnant or lactating or those women of child-bearing age that are not using acceptable forms of contraception~4. Diagnosis of asthma that is presently being treated with ANY medication, or past history of asthma/bronchospasm resulting in an emergency room visit, hospitalization or treatment~5. Unable to adhere to study protocol for whatever reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NAC in PD (Type: EXPERIMENTAL): single intravenous administration of N-acetylcysteine in PD patients
- NAC in GD (Type: EXPERIMENTAL): single intravenous administration of N-acetylcysteine in GD patients
- NAC in controls (Type: EXPERIMENTAL): single intravenous administration of N-acetylcysteine in control subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).